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1. Introduction 
Cancer is one of the most common diseases, which treat human life. It produces huge 
psychological, economical and social burdens. Enormous preventive, diagnostic and 
therapeutic research efforts have been done to eradicate this deadly disease. Though some 
success have been obtained in terms of disease control for some of the neoplasms such as 
some of the lymphoma types, thyroid cancer and for some of the other solid tumors such as 
breast cancer in case of early detection, most still are left as a deadly disease. On the other 
hand current treatment modalities including surgery or/and chemoradiotherapy bring a 
huge  hand local damage to the tissues and thus decrease the quality of life yet most shows 
recurrence and metastasis, which also questions the efficiency of these treatments.  
Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent cancers that 
lead to death, making it a major health problem in the world. HNSCC includes oral, 
oro/nasopharyngeal and laryngeal cancers and accounts for more than 644,000 new cases 
worldwide, with a mortality of 0.53 and a male predominance of 3:1 [1,2]. Despite advanced 
technology in the detection and treatment of HNSCC, it continues to pose a great threat for 
human life. Most patients suffering from this malignancy are at an advanced stage upon 
diagnosis in which 51% present regional metastasis and 10% with distant metastasis. The 5-
year relative survival rate with regional metastasis is about 51% and with distant metastases 
is 28% [1,3]. 
Though much development has been obtained in surgical techniques, chemoradiation 
protocols, little progress was shown in terms of long-term survivals during several decades. 
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Moreover, surgery now one of the main therapeutic options in these cancers gives rise to 
extensive local damage. Many patients lose partially or completely the organs in head and 
neck area, which have important functions such as speaking, eating, swallowing and 
respiration. Thus these patients finally fall into huge psychological and functional  
burden. On the other hand, last 2-3 decades provided great developments and progress in 
human genome technology, which warranted development novel diagnostic and 
therapeutic methods, which are finally supposed to be more effective and to preserve 
functional properties. 
As for most cancer types, head and neck cancer is basically a genetic associated disease. 
Cumulative alterations of various genes are responsible for development of this cancer type. 
Environmental and personal factors such as smoking, drinking, dirty air, exposure to 
carcinogenic chemicals through working environment or foods finally influence on genes. 
These affected genes are altered either as genetically or epigenetically and mutated 
nonfunctional or deficient products then result in cancer development.  
Our current knowledge on human genome showed that two major groups of tumor-
associated genes, oncogenes and tumor suppressor genes (TSG) have been implicated in the 
carcinogenic process (Figure 1). In normal cell, a critical balance between TSG and 
oncogenes is necessary for physiological survival of the cell. In normal cell, product of 
oncogene is needed for its proliferation, survival and growth. On the other hand, TSG is 
necessary for balancing and suppressing excessive growth of the cell and entering into 
carcinogenic process. Most oncogenes are growth factors or their receptors, as well as 
various molecules of signaling pathways, proapoptotic genes, cell cycle proteins and 
transcription factors. These proteins finally induce cell cycle, proliferation and growth. As 
same for most genes, oncogenes have two alleles in nuclear genome. Role of oncogenes in 
human cancer is mediated through enforcement of protein function upon activated 
mutation of one of the alleles in its genomic location. The rest allele is usually not affected 
and final output is more cell proliferation, growth and cancer when other factors such 
inactivation of tumor suppressors, inability of immunological as well as apoptotic 
mechanisms are added. 
On the other hand, tumor suppressors have been defined as genetic elements whose 
inactivation allows cell to display one or more phenotypes of neoplastic growth [4]. 
Products of TSG usually include inhibitors of cell cycle, chromatin remodeling factors, anti-
apoptotic genes and some genes regulating gene expression at genetic and epigenetic levels. 
Similar to oncogenes, TSG also consist of two copies at their chromosomal loci. Inactivation 
of TSG leads to carcinogenic process. Until recently, Knudson two-hit hypothesis has been 
known as an explanation of inactivation of TSG during carcinogenesis [5]. According to this 
hypothesis, one of the alleles of a TSG is lost through carcinogenic effect, while the rest allele 
is usually inactivated through mutation of the gene (Figure 2). However, a novel class of 
TSG with haploid insufficiency, in which one allele is lost and the remaining allele is haplo-
insufficient, has been described recently, and the patients with these hemizygous TSG in 
their genome are accepted as carriers for deficient allele of a TSG and they show a tumor-
prone phenotype especially when challenged with carcinogens such as smoking, alcohol, x-
ray, chemicals etc (Class II TSG) [6-10]. 
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Fig. 1. Schematic representation of two major groups of genes on cell growth and cancer 
development. 
 
Fig. 2. Schematic representation of two-hit mechanism for inactivation of tumor suppressor 
gene 
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In the current review, we will focus on a recently identified TSG group, ING family tumor 
suppressors. Thus this review will mainly include alterations of ING family tumor 
suppressor in human cancer and their possible applications in molecular diagnosis and 
therapy of cancer. The five members of the ING family were recently identified by our 
group and other researchers in the field [11-17]. All proteins of ING family genes contain a 
highly conserved plant homeodomain (PHD) finger motif in the carboxy (C)-terminal end 
that is commonly detected in various chromatin remodeling proteins [18,19]. The N-terminal 
part of each ING protein seems to be unique, which determines the structure and different 
functions of various ING genes [11,12,16]. Although exact functions of ING family genes 
have not been clarified, the gene products have been reported to be involved in 
transcriptional regulation, apoptosis, cell cycle, angiogenesis and DNA repair through p53-
dependent and –independent pathways. Moreover, ING family genes have also been known 
to constitute complexes with histone acetyltransferases (HAT) and histone deacetylases 
(HDAC) [11, 12, 16,20].  
Within the members, ING1 is the founding member and thus most information about the 
family genes comes from the researches on ING1. ING1 was first isolated using subtractive 
hybridization between short segments of cDNAs from normal and a number of breast 
cancer cell lines [21]. These randomly fragmented cDNAs interfered with the activity of 
tumor suppressors by either blocking protein production through anti-sense sequences or 
abrogating function in a dominant-negative fashion through truncated sense fragments [21]. 
The other four members of ING gene family have been identified through sequence 
homologies with ING1, followed by functional in-vitro and then in-vivo cancer patient 
tissue analysis [11,12,19,22,23]. 
We characterized the genomic structure of ING1 gene and showed that ING1 gene 
produced at least 4 mRNA variants from 3 different promoters for the first time. Two of 
these variants, p33ING1b consisting of exons 1a and 2, and p24ING1c consisting of a 
truncated p47ING1a message including the first ATG codon in exon 2, are expressed 
majorly, while p47ING1a consisting exon 1b and exon 2, was not detected in head and neck 
tissues [13]. Our continuous efforts led to identification of ING3 [14]. Following these works, 
other groups and our group published investigations on other members of ING family 
including ING2, ING4 and ING5 [15,16,24-32]. Although almost all of the ING family 
members are known to be negative regulator of the cell growth, recent studies also 
demonstrated some of the members or splicing variants also functioning as oncogene, thus 
complicating the role of these genes in human carcinogenesis [31,32]. 
2. Disorders of ING family genes in human tumors 
Rearrangement of ING1 gene locus was demonstrated in one neuroblastoma cell line and 
reduced expression in primary cancers and cell lines in early clinical studies at the time of 
ING1 cloning [11-17,21]. Following ING1 cDNA cloning, we identified the genomic 
structure of the human ING1 gene and showed its tumor suppressor character for the first 
time by finding its chromosomal deletion at the 13q34 locus and tumor-specific mutations in 
a number of head and neck squamous cell carcinoma (HNSCC) samples [13].  
Regarding with the mRNA expression status of ING family genes, only a few studies exist in 
the literature. Toyama et al. detected 2–10-fold decreases in ING1 mRNA expression in 44% 
www.intechopen.com
Role of ING Family Genes in Head and Neck  
Cancer and Their Possible Applications in Cancer Diagnosis and Treatment 
 
145 
of breast cancer and in all of 10 breast cancer cell lines examined [33]. Interestingly, the 
majority of breast cancers showing decreased ING1 expression had metastasized to regional 
lymph nodes, whereas only a small subset of cancers with elevated ING1 expression 
compared to adjacent normal tissues were metastatic. Another study also revealed reduced 
expression of breast cancer samples [34]. Down-regulation of ING1 mRNA has also been 
demonstrated in various other cancer types, including lymphoid malignancies, gastric 
tumors, brain tumors, lung cancer, ovarian cancer and esophagogastric carcinomas, though 
no comprehensive clinical correlation was performed [11,12,17,20,35-43]. Uncommon 
missense mutations and reduced protein expression of ING1 have also been detected in 
esophageal carcinomas [44], and colon cancer cell lines [36] while no mutation was detected 
in leukemia [37,45], oral cancers [46] and lymphoid malignancies [35].  
For loss of ING gene and their protein functions, loss of heterozygosity (LOH), promoter 
CpG hypermetylation and nucleo-cytoplasmic protein mislocalization have been proposed 
[11,12,17,20]. Using methylation-specific PCR, the p33ING1b promoter was methylated and 
silenced in almost a quarter of all cases in primary ovarian tumors [42]. No differences or 
increased expression of ING1 were observed in recent studies of myeloid leukemia or 
melanoma [45,47].  
Recently reduced expression of ING2 mRNA as well as protein was observed in 
hepatocellular carcinoma (HCC) [48]. Decreased ING2 expression (but not ING2 mutation) 
has been observed in lung cancer [49]. Decrease of nuclear ING2 protein was observed in 
melanoma [50]. On the other hand increased expression of ING2 mRNA was shown in colon 
cancer [51]. Moreover, ING2 may play a role in melanoma initiation, since reduction of 
nuclear ING2 has been reported in radial as well as vertical growth phases in metastatic 
melanoma as compared to dysplastic nevi [52]. On the other hand, reduced ING2 expression 
was associated with tumor progression and shortened survival time in HCC [48]. These 
epidemiological studies suggest that ING2 loss or reduction may be important for tumor 
initiation and/or progression [11,12,17,20].  
As shown for ING2, decreased nuclear ING3 protein expression was associated with a poor 
survival rate. The survival rate was 93% for the patients with strong nuclear ING3 staining, 
whereas it declined to 44% for the patients with negative-to-moderate nuclear staining [52]. 
In a recent study, we also demonstrated frequent deletion of chromosomal locus of each of 
ING family member including ING3 in ameloblastomas [53].  
ING4 mRNA was decreased in glioblastoma and associated with tumor progression [54]. 
Decreased ING4 has been associated with increased expression of IL-8 and osteopontin 
(OPN) in myeloma [11,55]. In both reports, decreased ING4 expression was associated with 
higher tumor grade and increased tumor angiogenesis. In myeloma, it was also associated 
with increased expression of interleukin-8 and osteopontin [11,55]. Expression of ING4 was 
decreased in malignant melanoma as compared to dysplastic nevi, and was found to be an 
independent poor prognostic factor for the patients [56]. ING4 was found to suppress the 
loss of contact inhibition and growth. Moreover some mutation and deletion were detected 
in cell lines derived from human cancers such as breast and lung [57]. 
Significant reduced expression of ING4 was detected in gliomas as compared with normal 
human brain tissue, and the extent of reduction correlated with the progression from 
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lower to higher grades of tumours [54]. Klironomos et al. investigated 
immunohistochemically the expression pattern of ING4, NF-kappaB and the NF-kappaB 
downstream targets MMP-2, MMP-9 and u-PA in human astrocytomas from 101 patients. 
They found that ING-4 expression was significantly reduced in astrocytomas, and it was 
associated with tumor grade progression. Expression of a NF-kappaB subunit p65 was 
significantly higher in grade IV than in grade III and grade I/II tumors, and a statistical 
significant negative correlation between expression of ING4 and expression of nuclear p65 
was noticed [58].  
Recently Nagahama et al. reported up-regulation of ING4 in a human gastric carcinoma cell 
line (MKN-1) by promoting mitochondria-mediated apoptosis via the activation of p53 [59]. 
Both mRNA and protein of ING4 expression were down regulated in hepatocellular 
carcinoma tissues. ING4 expression level correlated with prognosis and metastatic potential 
of hepatocellular carcinoma [60]. In another recent study, ING4 mRNA and protein 
expression were examined in gastric adenocarcinoma tissues and human gastric 
adenocarcinoma cell lines by RT-PCR, real-time RT-PCR, tissue microarray 
immunohistochemistry, and western blot analysis [61]. Their data showed that ING4 mRNA 
and protein were dramatically reduced in stomach adenocarcinoma cell lines and tissues, 
and significantly less in female than in male patients. Decrease of ING4 mRNA expression 
was found to correlate with the stage of the tumour [61]. Wang et al. examined ING4 protein 
expression in 246 lung cancer samples and overall reduced ING4 expression and higher 
ING4 expression in cytoplasm than in nucleus of tumour cells were detected, suggesting its 
involvement in the initiation and progression of lung cancers [62].  
Examination of ING4 protein expression levels in colorectal cancer samples from 97 patients 
showed that ING4 protein was down regulated in adenoma relative to normal mucosa and 
further reduced in colorectal cancer tissues. Decrease of ING4 protein expression was also 
related to the more advanced Dukes' stages and ING4 expression levels in patients with 
lymphatic metastasis were lower than those without metastasis, suggesting that ING4 play a 
role in colorectal carcinoma progression [63]. 
Xing et al. analyzed ING5 expression in gastric carcinoma tissues and cell lines (MKN28, 
MKN45, AGS, GT-3 TKB, and KATO-III) by Western blot and reverse transcriptase-
polymerase chain reaction. An increased expression of ING5 messenger RNA was  
found in gastric carcinoma in comparison with paired mucosa and lower expression of 
nuclear ING5 protein and cytoplasmic translocation was detected in gastric dysplasia and 
carcinoma than that in nonneoplastic mucosa [64]. Nuclear ING5 expression was negatively 
correlated with tumor size, depth of invasion, lymph node metastasis, and clinicopathologic 
staging, whereas cytoplasmic ING5 was positively associated with depth of invasion, 
venous invasion, lymph node metastasis, and clinicopathologic staging in colorectal 
carcinomas [65]. 
3. Abnormalities of ING family genes in head and neck cancer 
At the time of ING1 cloning, deletion of chromosome 13q34 was shown in head and neck 
cancer but ING1 gene was not known to be responsible for this deletion. Later in a 
comprehensive study, our group demonstrated tumor specific missense mutations in ING1 
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gene and frequent deletion at long arm of chromosome 13 for the first time in a human 
cancer [13]. Of 34 informative cases of head and neck squamous cell carcinoma, 68% of 
tumors showed loss of heterozygosity at chromosome 13q33-34, where the ING1 gene is 
located. By this study, ING1 has been recognized to be an important TSG at least in head 
and neck cancer. These mutations were found in the PHD zinc finger domain and putative 
nuclear localization signal, which may abrogate the normal function of ING1 protein  
(Figure 3). Following this study, our group led most of the researches for ING family genes 
in head and neck cancer. 
 
Fig. 3. Mutations detected at PHD zinc finger domain and nuclear localization signal (NLS) 
of ING1 protein, which may abrogate its function 
On the other hand, examination of 71 indian oral cancer cases demonstrated only 
polymorphic changes but not somatic possible function effective alterations [66]. However, 
analysis of esophageal cancer, which display some similarities especially for 
hypopharyngeal cancer, also demonstrated somatic mutations in ING1, supporting our 
results [44]. 
We recently demonstrated that frequent deletion of ING2 locus at 4q35.1 associated with 
advanced tumor stage in HNSCC [67]. LOH was detected in about 55% of the informative 
samples and high LOH frequency was statistically associated with advanced T stage, 
suggesting that ING2 LOH might occur in late stages during HNSCC progression. On the 
other hand, positive node status (N) appeared to be the only independent prognostic factor 
for both overall and disease free survivals. 
We showed frequent allelic loss of ING3 in HNSCC [14]. We analysed LOH at 7q31 region in 
49 HNSCC by using six polymorphic microsatellite markers and found allelic deletion in 48% 
(22/46) of the informative cases. We detected two preferentially deleted regions, one is around 
D7S643 and the other around D7S486. When we redefined the map of 7q31 region according to 
the contiguous sequences, a recently identified gene, ING3, was found in the proximity of 
D7S643. But ING3 mutation was very rare in our study (a sole missense mutation of ING3 at 
codon 20). In another recent our study using a large study population, about half of the 71 
tumor samples demonstrated downregulation of ING3 compared to their matched normal 
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counterparts. We revealed that down-regulation of ING3 was more evident in late-stage 
tumors as compared with early stage patients, and patients with low ING3 mRNA expression 
demonstrated worse survival rates as compared to the patients with normal-high ING3 
expression [68]. We also examined p53 mutation status and investigated its relationship with 
ING3, as well its clinicopathological characteristics. Although most clinicopathological 
variables were not significantly related to ING3 downregulation or p53 mutation status, a 
significant relationship was detected in terms of overall survival between the cases with low 
and normal to high ING3 expression. At 5 years follow up, approximately 60% of the patients 
with normal to high ING3 expression survived, whereas this was 35% in the patients with low 
ING3 expression. Multivariate analysis also showed downregulation of ING3 as an 
independent prognostic factor for poor overall survival. These results reveal that ING3 would 
function as a potential tumor suppressor molecule and that low levels of ING3 may indicate an 
aggressive nature of head and neck cancer. 
We analyzed loss of heterozygosity at 12p12-13 region in 50 head and neck squamous cell 
carcinomas by using six highly polymorphic microsatellite markers and found allelic loss in 
66% of the informative cases. To identify ING4 function, mutation analysis was performed. 
Though mutation of the ING4 gene was not found in head and neck cancers, the mRNA 
expression level examined by quantitative real-time RT-PCR analysis demonstrated 
decreased expression of ING4 mRNA in 76% of primary tumors as compared to matched 
normal samples. Since p53 dependent pathways of other ING family members have been 
shown, we examined p53 mutation status and compared with ING4 mRNA expression in 
tumor samples. However, no such direct relationship has been detected. In conclusion, 
frequent deletion and decreased mRNA expression of ING4 suggested it as a class two 
tumor suppressor gene and may play an important role in head and neck cancer [15].  
In a recent study, nuclear expression of ING4 was found to gradually decrease from non-
cancerous epithelium and dysplasia to HNSCC and was negatively correlated with a 
poorly-differentiated status, T staging, and TNM staging in HNSCC. On the other hand, 
cytoplasmic expression of ING4 was significantly enhanced in HNSCC and was 
significantly associated with lymph node metastasis and 14-3-3η expression. Moreover, 
nuclear expression of ING4 was positively correlated with p21 and p300 expression and 
with the apoptotic index. Their results suggested that the decreases in nuclear ING4 and 
cytoplasmic translocation of ING4 protein play important roles in tumorigenesis, 
progression and tumor differentiation in HNSCC [69].  
Our group reported the first study linking ING5 chromosome locus to a human cancer. We 
demonstrated a high ratio of LOH in oral cancer using 16 microsatellite markers on the long 
arm of chromosome 2q21-37.3 [24]. ING5 appeared to be a strong candidate tumor 
suppressor in this study though several other candidate TSGs including ILKAP, HDAC4, 
PPP1R7, DTYMK, STK25, BOK are also localized at the area, where frequent deletion has 
been detected [11,12,24]. Moreover, our recent study revealed decreased expression of ING5 
mRNA and mutations in oral cancer samples as compared to their corresponding normal 
controls, suggesting its tumor suppressive role in cancer [25]. Examination of 172 cases of 
HNSCC for ING5 protein by immunohistochemistry using tissue microarray, and in 3 oral 
SCC cell lines by immunohistochemistry and Western blot showed that a decrease in 
nuclear ING5 localization and cytoplasmic translocation were detected, supporting the 
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previous studies and strong involvement of ING5 in tumorigenesis and tumor 
differentiation in HNSCC [70]. 
4. Possible applications of ING family genes in molecular diagnosis and 
therapy of cancer 
So far most of the studies for possible applications of ING family genes in molecular 
diagnosis and therapy of cancer include cancer types other than head and neck cancer. 
However, ING family genes express ubiquitously and are involved in carcinogenesis of 
many cancer types especially in head and neck carcinogenesis. Thus the following section of 
the review is added as a model for possible application of ING family genes as diagnostic 
and therapeutic target. 
4.1 Use of ING family genes for prediction of cancer behavior  
4.1.1 Sub-cellular localization of ING proteins as a biomarker 
Most tumor suppressors contain nuclear transport signals that facilitate their shuttling 
between the nucleus and the cytoplasm. This type of dynamic intracellular movement not 
only regulates protein localization, but also often impacts on function. Shuttling of tumor 
suppressor proteins between nucleus and cytoplasm has been reported to be involved in the 
regulation of cell cycle and proliferation. Deregulation of the nucleocytoplasmic cargo 
system results in the mislocalization of TSG proteins, which then alter function of TSG 
proteins [71]. The mistargeting of tumor suppressors can finally reveal direct cellular 
consequences and potentially lead to the initiation and progression of cancer. Abnormalities 
in nucleocytoplasmic cargo system leading the mislocalization of tumor suppressors were 
reported for p53, BRCA1, APC, VHL, BRG1 and ING1, and these abnormalities driven by 
genetic and epigenetic alterations in the tumor suppressor or their partners generally occur 
during the carcinogenic process [72-76]. For ING1, 2 of 3 different tumor specific somatic 
mutations that we detected in head and neck cancer were located at or near nuclear 
targeting domain, which could possibly abolish its functions through accumulation of the 
protein in the cytoplasm instead of in the nucleus [13].  
In a recent study, Nouman et al. reported that translocation of p33ING1b from the nucleus 
into the cytoplasm of melanocytes may have an important role in the development and 
progression of melanomas [77]. Immunostaining with new monoclonal antibodies (MAb) of 
GN1 and GN2 showed that ING1b product, a nuclear protein, was accumulated in the 
cytoplasm and was closely associated with malignant melanoma development. The authors 
suggested that detection of this subcellular mobilization with MAb ING1b may be an early 
indicator and could be of value in diagnostic approach.  
In another study of Nouman et al. nuclear expression of p33 (ING1b) was decreased in 
breast cancer cells, both in intensity and proportion of the cells stained. Reduction in nuclear 
expression of ING1 protein was associated with enhanced cytoplasmic p33 (ING1b) 
expression in a considerable number of cases. Those cases, which show p33 (ING1b) protein 
mislocalization, were also associated with more poorly differentiated tumors. Thus the 
authors suggested that p33 (ING1b) expression could be used as a marker of differentiation 
in invasive breast cancer. These results support the view that loss of p33 (ING1b) in the 
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nucleus may be an important molecular event in the differentiation and pathogenesis of 
invasive breast cancer [78].  
Similarly loss of nuclear expression of p33 (ING1b) was detected in 78% of cases of acute 
lymphoblastic leukemia (ALL). This loss in nuclear expression was associated with 
increased cytoplasmic expression of the protein. Kaplan Meier survival analysis 
demonstrated a trend towards a better prognosis for patients with tumors that had lost 
nuclear p33 (ING1b), suggesting that the loss of nuclear p33 (ING1b) expression may be an 
important molecular event in the pathogenesis of childhood ALL and can be used as a 
biomarker for prognosis [79].  
In another similar study, Vieyra et al. demonstrated that sub-cellular mislocalization of 
p33ING1b is a commonly seen in gliomas and glioblastomas [80]. Overexpression and 
aberrant localization of ING1b into the cytoplasm were observed in all of the 29 brain 
tumors. p33 (ING1b) normally contains a nuclear targeting sequence [11,12,16]. It has been 
previously demonstrated that altered sub-cellular localization of p33 (ING1b) abrogates its 
proapoptotic functions [81]. Loss of targeting domains that ensure the proper intracellular 
localization of p33 (ING1b) or physical association of ING with p53 could account for the 
abnormal localization of p33 (ING1b) in cancer. Recent experimental observations, including 
post-translational stabilization of p53 by p33 (ING1b) [82], and the discovery of the p53 
associated a parkin-like cytoplasmic-anchoring protein, PARC [83] and its p53-regulatory 
role support the possibility that association of ING proteins with p53 could account for the 
abnormal localization. Further studies in this field will clarify this point.  
For a normal function of ING1, the protein should be in the nucleus. ING1b protein 
phosphorylated on serine residue at position 199 has been reported to bind 14-3-3 proteins 
and subsequently be exported from the nucleus [84]. It has recently been shown that ING1 
also binds karyopherin proteins and that disruption of this interaction affects subcellular 
localization and activity of the ING as a transcriptional regulator [84].  
For ING1, few studies exist regarding with its subcellular localization. However for other 
member of ING family proteins, it mostly remains unkown and only few studies exist for 
subcellular alterations during carcinogenesis. Similar to the study of Nouman et al. [77] 
nuclear ING3 expression was found to be remarkably reduced in malignant melanomas 
compared with dysplastic nevi, which was significantly correlated with the increased ING3 
level in cytoplasm. Moreover the reduced nuclear ING3 expression was significantly 
correlated with a poorer disease-specific 5-year survival of the patients with primary 
melanoma, especially for the high-risk melanomas with the survival rate reducing from 93% 
for patients with strong nuclear ING3 staining in their tumor biopsies to 44% for those with 
negative-to-moderate nuclear ING3 staining. Interestingly, the multivariate Cox regression 
analysis revealed that reduced nuclear ING3 expression is an independent prognostic factor 
to predict patient outcome in primary melanomas [85].  
By using tissue microarray technology and immunohistochemistry, ING2 expression in 
human nevi and melanoma biopsies was examined. The data showed that nuclear ING2 
expression was significantly reduced in radial and vertical growth phases, and metastatic 
melanomas compared with dysplastic nevi. Reduced ING2 has been suggested as an 
important indicator in the initiation of melanoma development [86].  
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 In a recent study, the subcellular localization of ING4 has been shown to be modulated by 
two wobble-splicing events at the exon 4-5 boundary, causing displacement from the 
nucleolus to the nucleus. The authors provided evidence that ING4 was degraded through 
the ubiquitin-proteasome pathway and that it is subjected to N-terminal ubiquitination. It 
has also been demonstrated that nucleolar accumulation of ING4 prolongs its half-life, but 
lack of nucleolar targeting potentially increases ING4 degradation. Taken together, data of 
this work suggested that the two wobble-splicing events at the exon 4-5 boundary 
influenced subnuclear localization and degradation of ING4 [87].  
ING4 has been reported to interact with a novel binding partner, liprin alpha 1, which 
results in suppression of the cell spreading and migration [88]. Liprin α1/PPFIA1 (protein 
tyrosine phosphatase, receptor type f polypeptide) is known to be a cytoplasmic protein 
necessary for focal adhesion formation and axon guidance. Cytoplasmic ING4 may regulate 
cell migration through interacting with liprin α1, and with its known anti-angiogenic 
function, may prevent invasion and metastasis. This interaction could explain the specific 
property of ING4 from other ING proteins.  
In summary, sub-cellular localization of ING proteins or their interaction partners could be 
detected with various molecular and immunohistopathological methods and may be used 
as a biomarker for the behavior of the tumor and prediction of the disease progress. 
4.1.2 Genetic and epigenetic alterations of TSG as prognostic biomarker  
Alterations in allelic status, expression of mRNA and/or protein of the ING family genes 
provide potential usage of these genes as biomarkers in human cancer. Regarding with 
relation between genetic alterations of various genes and clinical outcome has recently been 
investigated. Since only few studies regarding with ING family genes exist in the literature, 
we will first give examples, which has been reported for other genes and summarize those 
published for ING tumor suppressors. In such a research, FHIT gene methylation has been 
found as a prognostic marker for progressive disease of early lung cancer [89]. Methylation 
and LOH analysis of FHIT gene showed that loss or reduced FHIT expression was 
significantly associated with squamous cell carcinoma type and smokers. Also methylation 
in normally appearing lung mucosa was related with an increased risk for progression into 
lung cancer, suggesting that FHIT can be used as a biomarker for this cancer type. In 
another report, allelic loss at 3p and 9p21 was related with elevated risk of malignant 
transformation of the premalignant lesions in head and neck cancer [90]. Similarly LOH at 
8p was a predictor for long-term survival in hepatocellular carcinoma [91]. 
Another study highlighted the prognostic role of p16 in predicting the recurrence-free 
probability in patients affected by low-grade urothelial bladder by using p16 expression and 
LOH at 9p21 and proved the fact that the method is likely to be used in everyday urologic 
clinical practice to better describe the natural history of urothelial bladder carcinomas [92]. 
LOH at 16q23.2 was shown to be a predictor of disease-free survival in prostate cancer [93]. 
Our group has recently demonstrated that deletion at chromosome 14q was associated with 
poor prognosis in head and neck squamous cell carcinomas [1]. We also showed that 
frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and 
neck squamous cell carcinoma [67]. Interestingly, in our study, deletion at Dickkopf (dkk)-3 
locus (11p15.2) was detected to be related with lower lymph node metastasis and better 
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prognosis in head and neck squamous cell carcinomas, suggesting the different nature of 
this gene, yet its potential use as a prognostic biomarker [94].  
Detection of a gradual increase of mRNA expression of the DNA replication-initiation 
proteins from epithelial dysplasia (from mild through severe) to squamous cell carcinoma of 
the tongue has been used as biomarker to distinguish precancerous dysplasia from SCC and 
is useful for early detection and diagnosis of SCC as an adjunct to clinicopathological 
parameters [95]. In a recent work, we demonstrated downregulation of TESTIN and its 
association with cancer history and a tendency toward poor survival in head and neck 
squamous cell carcinoma [96]. The increased serum midkine concentrations were strongly 
associated with poor survival in early-stage oral squamous cell carcinoma, suggesting it as a 
useful marker not only for cancer screening but also for predicting prognosis of OSCC 
patients [97].  
Information on human genome project provided that many gene including cancer-
associated genes show alternative splicing. In such a study, deregulation of survivin splicing 
isoforms has been shown to influence significant implications in tumor aggressiveness and 
prognosis [98]. In ING family genes, some of the members also have splicing variants. 
Although we don’t have detail study for these variants, their deregulation may have an 
impact for carcinogenesis. In our work, two major variants of ING1 (p33ING1 and p24ING1) 
revealed different expression patterns. Our researches indicated alternative splicing variants 
for ING1, ING3, ING4 and ING5 [13-15,25]. For ING2, a recent study reported 2 splicing 
variants [31,32]. Though both of them showed decreased expression in head and neck cancer 
tissues as compared to the normal counterparts, methylation analysis demonstrated that 
only p33ING1 variant was associated with methylation (Gunduz et al. unpublished data). 
Not only single gene alterations associated with clinical outcome but also genome-wide or 
microarray studies were also examined. In such as study, genome-wide transcriptomic 
profiles obtained for 53 primary oral cancer and 22 matching normal tissues exhibited up-
regulated genes and down-regulated genes. In conclusion, this study provided a 
transcriptomic signature for oral cancer that may lead to a diagnosis or screen tool [99]. In a 
recent study, the expression levels of ITGA3, ITGB4, and ITGB5 with functional 
normalization by desmosomal or cytoskeletal molecule genes were shown as candidate 
biomarkers for cervical lymph node metastasis or for the outcome of death in oral  
cancer [100].  
Another recent study identified allelic deletion of ING1 as a novel genomic marker as 
related progression to glioblastoma by using comparative genomic hybridization and DNA 
microarray [101]. In another study, low levels of ING1 mRNA have been reported to be 
significantly associated with poor prognosis in neuroblastoma [102]. The expression level of 
ING1 was also closely related to survival. These results suggest that decreased level of ING1 
mRNA and/or protein expression could be an indicator of poor prognosis in advanced 
stages and/or poor survival of various human tumors. On the other hand, an association 
between p33ING1b protein expression and clinical outcome in colorectal cancer 
demonstrated that although patients with decreased p33ING1b protein expression in the 
tumor have a shorter overall and metastasis-free survival rate as compared with patients 
with normal p33ING1b protein expression, no statistical significance was achieved [103]. 
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However a significant association between p53 mutation status and overall and metastasis-
free survival has been found.  
Regarding with ING2 gene, its reduced mRNA as well as protein expressions were shown to 
be associated with tumor progression and shortened survival time in HCC [48]. Recently, 
our group reported that high LOH frequency in ING2 locus at 4q35.1 was significantly 
associated with advanced tumor stage in HNSCC, suggesting that ING2 LOH might occur 
in later stages during HNSCC progression [67]. Hence, the relevance of ING2 in HNSCC 
carcinogenesis and the potential prognostic significance of ING2 are promising results for 
future studies.  
Several recent studies examined correlation between ING3 protein expression and 
clinicopathological variables [52,54]. Interestingly, significant reduction of nuclear ING3 was 
detected in human malignant melanoma, indicating the status of ING3 as a prognostic and 
therapeutic marker for melanoma [52]. As it has been shown for ING2, decreased nuclear 
ING3 protein expression was also associated with a poorer 5-year survival rate. The survival 
rate was 93% for the patients with strong nuclear ING3 staining, whereas it decreased to 
44% for the patients with negative-to-moderate nuclear staining. We have recently reported 
mRNA expression of ING3 in HNSCC and compared the clinicopathological characteristics 
to evaluate its prognostic value as a biomarker [14,68]. This study revealed that down-
regulation of ING3 was more evident in late-stage tumors as compared with early stage 
cases. Analyses have also showed that down-regulation of ING3 could be used as an 
independent prognostic factor for poor overall survival and low levels of ING3 may indicate 
an aggressive nature of HNSCC.  
Recently the correlation of the ING4 with patient survival and metastasis was revealed to be 
as a potential prognostic marker in melanoma [56]. It has been found that ING4 expression 
was significantly decreased in malignant melanoma compared with dysplastic nevi, and 
overexpression of ING4 inhibited melanoma cell invasion compared with the control.  
4.1.3 ING genes as chemosensitivity marker 
Overall survival of head and neck squamous cell carcinoma patients has not improved in 
the decades. Currently treatment strategies for this cancer are based on the tumor-node-
metastasis (TNM) classification. However, due to the extreme biological heterogeneity of the 
cancer cells, treatment planning especially for chemoradiotherapy is quite difficult and 
chemotherapy is an important therapeutic modality for cancer, and identification of the 
genes that predict the response of cancer cells to these agents is critical to treat the patients 
more efficiently. Although clinical determinants such as TNM classification will be still 
important, it is now becoming possible, by molecular markers, to elucidate biological 
information about host and tumor, to break through the molecular heterogeneity and 
eventually to optimize the choice of treatment [104].  
In a recent analysis for prediction of chemosensitivity, it has been reported that examining 
the TP to DPD ratio of their tumors could identify HNSCC patients, who would most 
benefit from capecitabine-based chemotherapy. Moreover, the potential role of TP gene 
therapy in TP to DPD ratio manipulation to optimize the tumoricidal effect of capecitabine 
has been demonstrated [105]. In another similar study, acquired (10-fold) resistance of 
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Cal27, a tongue cancer cell line, against cisplatin has been shown to be associated with 
decreased DKK1 expression and this resistance could partially be reversed by DKK1 
overexpression, thus suggesting DKK1 and the WNT signaling pathway as a marker and 
target for cisplatin chemosensitivity [106].  
Recent findings suggest that the ING genes might also have a role in regulating the response 
of cancer cells to chemotherapeutic agents. In an osteosarcoma cell line, U2OS cells, one of 
the ING1 splicing variant p33ING1b, prominently enhanced etoposide-induced apoptosis 
through p53-dependent pathways [107]. In another study of the authors, ectopic expression 
of p33ING1b was shown to upregulate p53, p21WAF1 and bax protein levels and activate 
caspase-3 in taxol-treated U2OS cells. Thus the study demonstrated that p33ING1b 
increased taxol-induced apoptosis through p53-dependent pathway in human osteosarcoma 
cells, suggesting that p33ING1b may be an important marker and/or therapeutic target in 
the prevention and treatment of osteosarcoma [108]. 
Tallen et al. [39] questioned whether p33ING1 mRNA expression correlates with the 
chemosensitivity of brain tumor cells. They found that, unlike other tumor types, ING1 
levels were higher in glioma cell lines than in normal control cells. Medulloblastoma cells 
revealed the lowest ING1 expression of the lines tested. Comparing all cell lines, p33ING1 
gene expression significantly correlated with resistance to vincristine, suggesting that 
p33ING1 mRNA levels may be used to predict the chemosensitivity of brain tumor cells  
to vincristine.  
The tumor suppressor ING1 shares many biological functions with p53 including cell cycle 
arrest, DNA repair, apoptosis, and chemosensitivity. To investigate if the p33ING1 isoform 
is also involved in chemosensitivity, Cheung et al. overexpressed p33ING1 in melanoma 
cells and examined for cell death after treatment with camptothecin. Results from the 
survival assay and flow cytometry analysis showed no significant difference among cells 
transfected with vector, p33ING1, and antisense p33ING1, indicating that p33ING1 does not 
enhance camptothecin-induced cell death in melanoma cells. Moreover, co-transfection of 
the p33ING1 and p53 constructs had also no effect on the frequency of cell death. Thus 
influence of ING1 expression for chemosensitivity may have different depending on the 
cancer type [109]. In another work, down-regulation of ING1 in the p53-deficient 
glioblastoma cell line, LN229, increased apoptosis following treatment with cisplatin, 
indicating that reduced ING1 expression may predict the sensitivity of cancer cells to 
chemotherapy independent of their p53 status [110]. Although most studies reported  
that expression of ING genes results in an increase in chemosensitivity, various conditions 
in different tumors should be tested to predict exact chemotherapy response. These 
differences could also be related with expression variations of the alternative splicing forms 
of ING genes.  
Another member of ING family, ING4 negatively regulated the cell growth with significant 
G2/M arrest of cell cycle. Besides overexpression of ING4 enhanced the cell apoptosis 
triggered by serum starvation in HepG2 cells. Furthermore, the exogenous ING4 
upregulated endogenous p21 and Bax in HepG2 cells, but not in p53-deficient Saos-2 cells, 
suggesting that G2/M arrest induced by ING4 could be mediated by the increased p21 
expression in a p53-dependent manner, although there is no significant increase of p53 
expression in HepG2 cells. Moreover, HepG2 cells with exogenous ING4 could significantly 
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increase cell death, as exposed to some DNA-damage agents, such as etoposide and 
doxorubicin, implying that ING4 could enhance chemosensitivity to certain DNA-damage 
agents in HepG2 cells [111]. In another study, chemopreventive agent curcumin (diferuloyl 
methane) induced ING4 expression during the cell cycle arrest by a p53-dependent manner 
in glioma cells (U251) [112]. Therefore ING4 has been suggested for a possible role in the 
signaling pathways of the chemotherapeutic agents. 
4.2 Applications of ING family for gene therapy  
Cancer still poses a great treat to human life and classical treatment modalities have still 
failed to eradicate it. Developments in human genome technology and progress in 
knowledge of the genes provided us alternative methods such as gene therapy to cure this 
fatal disease. Currently researchers are working on several basic methods to treat cancer 
using gene therapy. Some of these methods target healthy cells i.e. immune system cells to 
enhance their ability to fight cancer. Other approaches directly involve cancer cells, to 
destroy them or at least to stop their growth. The later method usually involves restoration 
of the tumor suppressor genes. In tumor cells, ING transcript levels are now known to be 
often downregulated though mutations are very rare. However, as explained in the above 
sections, it has been now known that the inactivation of ING family genes at genetic and 
epigenetic levels has a major role in the carcinogenesis of various neoplasms. Considering 
involvement of ING tumor suppressors in many cancer types, it can be thought that ING 
family genes may be of potential target for molecular therapy in human cancer. However, 
only few preclinical studies exist to evaluate this potential. Thus this section will only give 
an image and possible speculations for using these genes in cancer therapy. 
Regarding the gene therapy of ING family genes in the literature, a few in vitro studies have 
been reported. In 1999, the introduction of ING1 gene using virus vectors was reported as a 
pioneer and a promising approach for the treatment of brain tumors [113]. Although 
adenovirus-mediated introduction of isolated ING1 transcript has inhibited the growth of 
glioblastoma cells, combined transduction of p33ING1 and p53 synergistically enhanced the 
apoptosis in these cells [113], suggesting that ING1 may function as a proapoptotic factor as 
well as enhancing the effect of p53.  
Another study has shown similar findings and supported the cooperative role of ING1 and 
p53 in esophageal cancer [114]. Co-introduction of ING1 and p53 induced more cell death as 
compared to single use of each gene transcript in esophageal carcinoma cells. Thus, the 
synergistic effect between p33ING1 and p53 for induction of apoptosis has been suggested 
for 2 different human cancers, i.e. esophageal carcinoma and glioblastoma. Considering 
these two in vitro studies, combined gene therapy of one or more ING family members 
with/without p53 emerged as a promising alternative therapy in those cases with the failure 
of single use of p53 gene therapy.  
Another method in gene therapy could be potentialisation of the introduced gene. In fact, a 
study showed that one of the ING1 splicing isoforms, p47ING1a, was differentially up-
regulated in response to cisplatin in human glioblastoma cells (LN229) that express ING1 
proteins and harbor mutated TP53, which might represent a response to protect DNA from 
this DNA-damaging agent. Thus ING1 down-regulation may sensitize glioblastoma cells 
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with deficient p53 to treatment with cisplatin. It was concluded that the status of p53-
independent-ING expression level might predict the relative sensitivity to treatment with 
cisplatin and HDAC inhibitors in glioblastoma. These studies suggest that molecular 
therapy of ING1 could be combined with chemotherapeutics in a subset of human cancer.  
Interestingly, some of ING family members have additional functions for suppressing the 
tumor growth such as anti-angiogenesis for ING4. Thus future studies using other members 
alone or in combination for gene therapy will provide more successful and promising 
results. In fact, it has been shown that ING4 gene therapy may be effective in human lung 
carcinoma as a novel anti-invasive and anti-metastatic agent [115]. Adenovirus-mediated 
ING4 expression suppressed the tumor growth and cell invasiveness in A549 lung cancer 
cells, suggesting that ING4, as a potent tumor-suppressing agent, present great therapeutic 
potential. Another interesting study displayed that ING4 inhibited MMP-2 and MMP-9 
expressions in melanoma cells, which may contribute to the suppression of melanoma cell 
invasion [56]. This study demonstrated that overexpression of ING4 significantly decreased 
melanoma cell invasion by 43% and suppressed cell migration by 63%. Since degradation of 
basement membrane and extracellular matrix (ECM) is the first step in the invasion and 
metastasis of malignant tumors, down-regulation of the MMP-2 and MMP-9 expressions 
with Ad-ING4 may be a potential method in suppressing degradation components of the 
ECM and basement membrane and thus metastasis. In this respect, association of the ING4 
with the MMP pathway may open a new avenue and offer novel opportunities for 
molecular therapy of cancer. In another recent study, Xie et al. [116] demonstrated that Ad-
ING4-mediated transfection of PANC-1 human pancreatic carcinoma cells inhibited cell 
growth, altered the cell cycle with S-phase reduction and G2/M phase arrest, induced 
apoptosis, and downregulated interleukin (IL)-6 and IL-8 expression of transfected tumor 
cells. In athymic mice bearing the PANC-1 human pancreatic tumors, intratumoral 
injections of Ad-ING4 suppressed the tumor growth, downregulated CD34 expression, and 
reduced the tumor microvessel formation. Therefore, this study provided a framework for 
future clinical application of Ad-ING4 in human pancreatic and other carcinoma  
gene therapies. 
In conclusion, these reports suggest that the transfer or forced expression of ING4 into 
cancer cells by gene therapy also targets its related molecules such as MMPs. Thus 
combination of ING4 gene therapy with chemicals, which inhibit MMPs, could be a 
promising treatment method in various cancer types. In this respect, possible applications 
each member of ING family genes for gene therapy should be tested. A summary of ING 
gene alterations and their use as possible biomarkers and consequences of the gene 
restoration in cancer are shown in Figure 4. 
5. Future aspects 
Over a decade of research on the ING family genes has revealed that ING genes are 
involved in various functions from chromatin remodeling to cell cycle suppression and 
apoptosis. Moreover ING family genes also cooperate with major tumor suppressor p53 and 
make complexes with HAT and HDAC. Alterations of these genes occur commonly in many 
cancer types. Recent studies also suggest that allelic deletion or down-regulation of mRNA  
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Fig. 4. Alterations of ING family genes and their possible use as biomarker for diagnosis and 
gene therapy in cancer 
expressions as well as change of subcellular localization of proteins of the genes are likely to 
be used as a prognostic or predictive marker in human cancer. Today many cancer types 
including head and neck are treated based on clinical staging and findings such as lymph 
node involvement, TNM stage. However these clinical markers are most time not enough to 
follow tumor behavior or patients response to the therapy. Thus new methods are 
warranted to overcome these shortcomings to get a better response to the therapy or to 
predict which therapeutic method is best for each patient. At this point, involvement of ING 
genes in p53 tumor suppressor pathways and crosstalk between the variant of a single ING 
gene need to be clarified for focusing on INGs as diagnostic biomarkers. Progress on the 
knowledge of functions of ING family genes as well as the relationship with p53 and other 
unknown molecules will elucidate their roles in the development of human cancers, which 
will result in their uses in cancer diagnostics as well as therapy. 
Cancer today is still one of the most dangerous diseases for human life. So far for treatment 
of cancer, surgery and chemoradiotherapy are the major therapies. Major difficulty for 
treatment of the cancer is inefficiency of chemoradiotherapy since each person gives 
different response to the therapy. So far clinical staging or findings is used to plan for 
treatment of cancer. However, this is not enough since many patients are resistant to these 
therapies and there is currently no way to understand efficiency of these methods. Moreover 
these treatment modalities are not specific and demonstrate high toxicities. Recent 
developments in human genome and technology provide novel methods for prediction of 
therapy or tumor behavior as well as tumor-targeted specific therapeutic methods. Thus 
although development of many molecular biomarkers for prediction of tumor behavior are 
tested and genetic therapy trials are ongoing, five-year later it is likely to see some of these 
methods as routine clinical use. For example, LOH of some TSG loci or expression profiles 
of single or multiple genes or mutation status could direct our therapy and we can have a 
nearly 100% success for each patient since the treatment will be individualized based on use 
of multiple molecular biomarkers. Some of these markers could be developed based on the 
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studies on ING family genes. Furthermore, current gene therapies using mostly p53 gene as 
a tumor suppressor could be expanded to members of ING family genes or combined of 
various tumor suppressors. Besides gene therapy can also be considered to combine with 
chemoradiotherapy. 
6. Key points 
ING family genes are recently identified major tumor suppressor involved in many cancer 
types. 
ING family tumor suppressors have wide functions from cell growth, cell cycle suppression, 
DNA repair, chromatin remodeling to apoptosis. 
ING family genes also cooperate with other tumor suppressors such as p53 and HAT and 
HDAC. 
Alterations of ING genes at genetic and epigenetic level as well as their proteins showed 
promising results for their use as a molecular biomarker. 
These genes are also likely to be used for gene therapy as a single agent or combined with 
other tumor suppressors.  
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